These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

195 related items for PubMed ID: 9049860

  • 1. Ex vivo expansion of tumor-draining lymph node cells using compounds which activate intracellular signal transduction. II. Cytokine production and in vivo efficacy of glioma-sensitized lymphocytes.
    Rice CD, Baldwin NG, Biron RT, Bear HD, Merchant RE.
    J Neurooncol; 1997 Mar; 32(1):29-38. PubMed ID: 9049860
    [Abstract] [Full Text] [Related]

  • 2. Ex vivo expansion of tumor-draining lymph node cells using compounds which activate intracellular signal transduction. I. Characterization and in vivo anti-tumor activity of glioma-sensitized lymphocytes.
    Baldwin NG, Rice CD, Tuttle TM, Bear HD, Hirsch JI, Merchant RE.
    J Neurooncol; 1997 Mar; 32(1):19-28. PubMed ID: 9049859
    [Abstract] [Full Text] [Related]

  • 3. Incubation of antigen-sensitized T lymphocytes activated with bryostatin 1 + ionomycin in IL-7 + IL-15 increases yield of cells capable of inducing regression of melanoma metastases compared to culture in IL-2.
    Le HK, Graham L, Miller CH, Kmieciak M, Manjili MH, Bear HD.
    Cancer Immunol Immunother; 2009 Oct; 58(10):1565-76. PubMed ID: 19198835
    [Abstract] [Full Text] [Related]

  • 4. Bryostatin 1/ionomycin (B/I) ex vivo stimulation preferentially activates L-selectinlow tumor-sensitized lymphocytes.
    Chin CS, Miller CH, Graham L, Parviz M, Zacur S, Patel B, Duong A, Bear HD.
    Int Immunol; 2004 Sep; 16(9):1283-94. PubMed ID: 15262898
    [Abstract] [Full Text] [Related]

  • 5. Antitumor activity against established intracerebral gliomas exhibited by cytotoxic T lymphocytes, but not by lymphokine-activated killer cells.
    Holladay FP, Heitz T, Wood GW.
    J Neurosurg; 1992 Nov; 77(5):757-62. PubMed ID: 1403119
    [Abstract] [Full Text] [Related]

  • 6. gamma-Interferon plays a key role in T-cell-induced tumor regression.
    Tuttle TM, McCrady CW, Inge TH, Salour M, Bear HD.
    Cancer Res; 1993 Feb 15; 53(4):833-9. PubMed ID: 8428364
    [Abstract] [Full Text] [Related]

  • 7. Analysis of interleukin 2 and various effector cell populations in adoptive immunotherapy of 9L rat gliosarcoma: allogeneic cytotoxic T lymphocytes prevent tumor take.
    Kruse CA, Lillehei KO, Mitchell DH, Kleinschmidt-DeMasters B, Bellgrau D.
    Proc Natl Acad Sci U S A; 1990 Dec 15; 87(24):9577-81. PubMed ID: 2263613
    [Abstract] [Full Text] [Related]

  • 8. Expansion and tumour specific cytokine secretion of bryostatin-activated T-cells from cryopreserved axillary lymph nodes of breast cancer patients.
    Lind DS, Tuttle TM, Bethke KP, Frank JL, McCrady CW, Bear HD.
    Surg Oncol; 1993 Oct 15; 2(5):273-82. PubMed ID: 8305969
    [Abstract] [Full Text] [Related]

  • 9. Sensitizing T-lymphocytes for adoptive immunotherapy by vaccination with wild-type or cytokine gene-transduced melanoma.
    Lipshy KA, Kostuchenko PJ, Hamad GG, Bland CE, Barrett SK, Bear HD.
    Ann Surg Oncol; 1997 Jun 15; 4(4):334-41. PubMed ID: 9181234
    [Abstract] [Full Text] [Related]

  • 10. Retroviral transduction of interferon-gamma cDNA into a nonimmunogenic murine fibrosarcoma: generation of T cells in draining lymph nodes capable of treating established parental metastatic tumor.
    Shiloni E, Karp SE, Custer MC, Shilyansky J, Restifo NP, Rosenberg SA, Mulé JJ.
    Cancer Immunol Immunother; 1993 Oct 15; 37(5):286-92. PubMed ID: 8402732
    [Abstract] [Full Text] [Related]

  • 11. Correlation of the therapeutic effect of activated tumor-draining lymph node cells with specific interferon-gamma production in vitro.
    Sameshima S, Sakai K, Nagawa H, Tsuno N, Kitayama J, Muto T.
    Surg Today; 1999 Oct 15; 29(1):55-62. PubMed ID: 9934833
    [Abstract] [Full Text] [Related]

  • 12. IL-7 + IL-15 are superior to IL-2 for the ex vivo expansion of 4T1 mammary carcinoma-specific T cells with greater efficacy against tumors in vivo.
    Cha E, Graham L, Manjili MH, Bear HD.
    Breast Cancer Res Treat; 2010 Jul 15; 122(2):359-69. PubMed ID: 19826947
    [Abstract] [Full Text] [Related]

  • 13. Phenotype and functional activity of tumor-infiltrating lymphocytes isolated from immunogenic and nonimmunogenic rat brain tumors.
    Tzeng JJ, Barth RF, Orosz CG, James SM.
    Cancer Res; 1991 May 01; 51(9):2373-8. PubMed ID: 2015600
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Activation and growth of murine tumor-specific T-cells which have in vivo activity with bryostatin 1.
    Tuttle TM, Inge TH, Bethke KP, McCrady CW, Pettit GR, Bear HD.
    Cancer Res; 1992 Feb 01; 52(3):548-53. PubMed ID: 1732041
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Generation of therapeutic T cells from draining lymph nodes in a murine model of head and neck squamous cell carcinoma.
    Sadeghi N, Black MJ, Hier MP, Shenouda G, Karp SE.
    Arch Otolaryngol Head Neck Surg; 1997 Jan 01; 123(1):25-30. PubMed ID: 9006500
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Glioma-specific cytotoxic T cells can be effectively induced by subcutaneous vaccination of irradiated wild-type tumor cells without artificial cytokine production.
    Iwadate Y, Yamaura A, Sakiyama S, Sato Y, Tagawa M.
    Int J Oncol; 2003 Aug 01; 23(2):483-8. PubMed ID: 12851699
    [Abstract] [Full Text] [Related]

  • 20. Different cytokine profiles released by CD4+ and CD8+ tumor-draining lymph node cells involved in mediating tumor regression.
    Aruga A, Aruga E, Cameron MJ, Chang AE.
    J Leukoc Biol; 1997 Apr 01; 61(4):507-16. PubMed ID: 9103238
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.